205 related articles for article (PubMed ID: 19710697)
1. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells.
Karp M; Kosior K; Karczmarczyk A; Zając M; Zaleska J; Tomczak W; Chocholska S; Hus M; Dmoszyńska A; Giannopoulos K
Adv Clin Exp Med; 2015; 24(1):55-62. PubMed ID: 25923087
[TBL] [Abstract][Full Text] [Related]
4. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
[TBL] [Abstract][Full Text] [Related]
6. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
[TBL] [Abstract][Full Text] [Related]
8. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
9. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
10. Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.
Shao N; Ma D; Wang J; Lu T; Guo Y; Ji C
Ann Hematol; 2013 Jan; 92(1):33-9. PubMed ID: 22968660
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Abaza MS; Bahman AM; Al-Attiyah RJ
Int J Mol Med; 2014 Aug; 34(2):513-32. PubMed ID: 24899129
[TBL] [Abstract][Full Text] [Related]
14. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
15. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
18. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
[TBL] [Abstract][Full Text] [Related]
19. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
